Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient.
L Mole, D Israelski, J Bubp...
https://pubmed.ncbi.nlm.nih.gov/8417175Completed
Phase 1
Age: 18Years +
All Genders
ID00000661
The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2008-08-04
8
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
To determine if a pharmacokinetic (blood level) interaction exists between zidovudine (AZT) and oxazepam in the HIV-infected patient. Benzodiazepines (such as oxazepam) are among the most frequently prescribed class of drugs and are commonly used therapeutically for patients with chronic disease. This study is important because of the potential for toxicity resulting from a reaction between AZT and benzodiazepines and the likelihood of frequent use of the combination of these drugs in patients with HIV infection.
CONDITIONS
Official Title
The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Inclusion Criteria
Concurrent Medication:
Required:
- Stable prescribed dosage of zidovudine (AZT), = or > 500 mg/day.
Allowed:
- Prophylaxis for Pneumocystis carinii pneumonia (PCP) with aerosolized pentamidine.
- Erythropoietin.
Patients must be:
- HIV positive by ELISA and Western blot.
- Currently taking a stable prescribed dosage of 500 mg/day of zidovudine (AZT).
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
- Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT) therapy of = or < 600 mg/day.
- Significant underlying medical condition that could impair continuous participation in study.
- Malabsorption syndrome (3 or more loose stools a day for at least 4 weeks associated with an unintentional weight loss of at least 10 percent of body weight).
Concurrent Medication:
Excluded:
- Oral contraceptives.
- Cytotoxic chemotherapy.
- Ganciclovir.
- Flucytosine.
- Probenecid.
- Opiates.
- Valproic acid.
- Sulfa drugs.
- Sucralfate.
- Dapsone.
- Rifampin.
- Antacids within 2 hours of zidovudine (AZT) dose.
- Isoniazid.
- Ketoconazole.
- Pyrimethamine.
- Clindamycin.
- Aspirin.
- Ibuprofen.
- Investigational drugs not specifically allowed.
Patients with the following are excluded:
- Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT) therapy of = or < 600 mg/day.
- Significant underlying medical condition that could impair continuous participation in study.
- Unable to take oral medication reliably.
Prior Medication:
Excluded within 30 days of study entry:
- Antiretroviral agents other than zidovudine (AZT).
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
Trial Site Locations
Total: 1 location
1
Palo Alto Veterans Adm Med Ctr / Stanford Univ
Palo Alto, California, United States, 94304
Status Unknown
Loading map...
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
N/A
Model
N/A
Primary Purpose
TREATMENT
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here